Astellas’s latest annual report shows a rebound that is much more visible in profit than in sales alone. Revenue rose to ¥2.14 trillion in the year to March 2026 from ¥1.91 trillion a year earlier. Profit before tax climbed to ¥376.59 billion from ¥31.24 billion, while net profit attributable to owners of the parent reached ¥291.54 billion from ¥50.75 billion.
| Metric | Year to March 2025 | Year to March 2026 |
|---|---|---|
| Revenue | ¥1,912,323,000,000 | ¥2,139,245,000,000 |
| Profit before tax | ¥31,237,000,000 | ¥376,587,000,000 |
| Net profit attributable to owners of parent | ¥50,747,000,000 | ¥291,535,000,000 |
Revenue had already been moving in the right direction before this year. The report shows ¥1,603,672,000,000 in revenue for the year to March 2024, then ¥1,912,323,000,000 in the year to March 2025, and ¥2,139,245,000,000 in the latest year. Profit recovery lagged and then snapped back. Profit before tax was ¥24,969,000,000 in the year to March 2024 and only ¥31,237,000,000 in the following year, before jumping to ¥376,587,000,000 in the latest period. Net profit attributable to owners of the parent followed the same pattern, from ¥17,045,000,000 to ¥50,747,000,000 and then ¥291,535,000,000.
That distinction matters. Sales growth on its own would have been respectable pharma housekeeping. What changed the tone of this report is that earnings and return measures finally caught up. A year ago, Astellas still looked like a company with scale but not much bottom-line reward. The latest figures look more like a business that restored earning power. Basic earnings per share came in at ¥162.77, return on equity was 17.4%, and comprehensive income attributable to owners rose to ¥449,432,000,000 from ¥48,888,000,000 a year earlier.
The evidence surfaced here does not pin that rebound on a specific medicine, geography or pipeline event, so this is best read as a clean scorecard rather than a causation memo. It is also the company’s annual securities report for the year ended March 31, 2026, not a fresh guidance change dropped into the market mid-cycle. A separate internal control report concluded that the group’s financial-reporting controls were effective as of March 31, 2026.